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Abstract
Cefuroxime is widely used as antibiotic prophylaxis for orthopaedic procedures. We evaluated bone, 
subcutaneous tissue (SCT) and plasma pharmacokinetics of cefuroxime in male patients undergoing 
total knee replacement (TKR) after both traditional short-term infusion (STI) and continuous infusion 
(CI). Eighteen male patients undergoing TKR were randomly assigned to STI or CI of 1.5 g of 
cefuroxime. Measurements were obtained in plasma, SCT, cancellous and cortical bone every 30 min 
for 8 h following surgery. For sampling in solid tissues, microdialysis was applied. Population 
pharmacokinetic modelling were performed in order to estimate pharmacokinetic parameters, and to 
assess the probability of attaining cefuroxime concentrations above clinically relevant minimal 
inhibitory concentrations (MICs) for 65% and 90% of the 8 h dosing interval. Low SCT and cortical 
bone penetration were found in both the STI and the CI group, but the findings were only significant 
in the STI group. Irrespective of MIC, tissue and target, CI leads to improved probability of attaining 
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relevant pharmacokinetic targets compared to STI. For the Staphylococcus aureus MIC breakpoint (4 
μg/mL), STI leads to inadequate probability of target attainment. CI of 1.5 g of cefuroxime leads to 
improved probability of attaining relevant pharmacokinetic targets in male TKR patients compared to 
traditional STI. These findings suggest that application of CI may improve antibiotic prophylaxis for 
male TKR patients. 
Keywords: Cefuroxime, population pharmacokinetics, microdialysis, bone concentrations, 
continuous infusion 
Introduction
Prosthetic joint infections (PJI) is one of the most serious complications of joint replacement surgery. 
In addition to rigorous sterile measures, perioperative systemic antibiotic prophylaxis plays an 
important role in the prevention of postoperative infections. Although definite antibiotic target 
concentrations for this task are not established, it is advocated not only to achieve therapeutic 
concentrations in plasma but also in the relevant tissues throughout the surgical procedure (1). For 
most antibiotics, local perioperative tissue concentrations are currently unknown.
Cefuroxime is widely used as antibiotic prophylaxis for orthopaedic procedures because it provides 
coverage against a broad spectrum of both gram-positive and gram-negative bacteria including those 
most frequently responsible for PJIs (2). Cefuroxime is a second-generation cephalosporin, and like 
other beta lactams, the bactericidal activity is time-dependent. This means that its efficacy is best 
related to the time that the free concentration is sustained above the minimal inhibitory concentration 
of the invading pathogen (MIC) (fT>MIC) (3, 4). Traditionally, fT>MIC targets in plasma of 
approximately 40-70% of a dosing interval have been associated with clinical success (3, 5). 
However, recent clinical studies have suggested that more aggressive targets of 100% fT>1-5×MIC are 
more predictive of a successful outcome (6, 7). While definite targets for prevention of postoperative 
infection is lacking, the time-dependent activity of cefuroxime suggests that continuous infusion (CI) 
may provide favorable tissue exposure compared to standard short-term infusion (STI).
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In recent years, a number of studies have demonstrated that a homogeneous plasma-tissue distribution 
of antibiotics cannot be taken for granted (8-10). Consequently, a number of attempts have been made 
towards determination of bone concentrations of antibiotics. The predominant and traditional bone 
biopsy method suffers from important methodological limitations, and may not be ideal for the task 
(11-13). Recently, the pharmacokinetic tool microdialysis (MD) has been successfully applied for 
sampling of various antibiotics in drill holes in bone (8, 14-16). This approach seems to reflect the 
true perioperative situation.
In the present study, we set out to evaluate bone, subcutaneous tissue (SCT) and plasma 
pharmacokinetics of cefuroxime in male patients undergoing total knee replacement (TKR) after both 
CI and traditional STI using MD.
Materials and methods
This study was conducted at the Department of Orthopaedic Surgery, Horsens Regional Hospital 
between September 2013 and July 2014. Quantification of cefuroxime was performed at the 
Department of Clinical Biochemistry, Aarhus University Hospital. The study was approved by the 
Ethics Committee of the Central Denmark Region (registration number 1-10-72-161-13) and the 
Danish Health and Medicines Authority (EudraCT number 2013-001138-17). The study was 
conducted in accordance with the Declaration of Helsinki and the ICH Harmonized Tripartite 
Guideline for Good Clinical Practice. The GCP unit at Aalborg and Aarhus University Hospitals 
conducted the mandatory monitoring procedures.
Study patients and design
Competent male patients were offered enrolment in the study if they were scheduled for a TKR. The 
patients were identified in the outpatient clinic by the two operating surgeons. Written informed 
consent was obtained from all patients. Exclusion criteria included the following: allergy to 
cefuroxime or vancomycin, on-going treatment with cefuroxime, and clinically reduced renal 
function.
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Eighteen patients were included in the study. The study was designed as an open-labelled randomized 
controlled trial. Block randomization was applied with blocks of 6 patients, and an allocation ratio of 
1:1. The random allocation sequence was implemented using numbered envelopes (provided by the 
pharmacy at Aarhus University Hospital). According to the randomization, the patients were given 1.5 
g of cefuroxime (Fresenius Kabi AB, Sweden) intravenously in a peripheral catheter as STI (over 15 
min) or CI (0.5 g as loading dose over 5 min followed by CI of the remaining 1 g over 7 h and 55 
min). Cefuroxime was administered after the surgical procedures and calibration of the MD catheters. 
As preoperative antibiotic prophylaxis, all patients were given 1 g of vancomycin prior to surgery.
The primary outcome was the probability of attaining a traditional pharmacokinetic target of 65% fT 
> MIC and a more aggressive 90% fT > MIC target in the different tissues over an 8 h dosing interval. 
Area under the concentration-time curves (AUC) and tissue penetration ratios were secondary 
outcomes.
Surgery
At the end of TKR surgery, but before closing, MD catheters were placed in drill holes in cancellous 
bone in the medial tibial condyle and in cortical bone in the anterior margin of the tibial diaphysis as 
previously described (14). In addition to the bone catheters, a SCT catheter was placed in the medial 
part of the thigh. At the end of surgery, a mixture of 150 mL ropivacaine (2mg/mL), 1.5 mL toradol 
(30 mg/mL) and 0.75 mL adrenaline (1 mg/mL) was injected locally in the soft tissues surrounding 
the knee, intraarticularly and in the posterior joint capsule of the knee.
Microdialysis and sampling procedures
MD is a catheter-based method, which allows for continuous sampling of water-soluble molecules, 
like the majority of antibiotics, in the interstitial space of most tissues (8, 9, 17). The diffusion of 
molecules follows the concentration gradient across a semipermeable membrane at the tip of the 
catheter. As the catheter is continuously perfused, equilibrium will never occur. Consequently, the 
concentration of solutes in the dialysate (i.e. the perfusate leaving the catheter) only represents a 
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fraction of the actual concentration in the tissue. This fraction is referred to as relative recovery (RR). 
Accordingly, determination of RR for each separate catheter is imperative if absolute tissue 
concentrations are to be determined. In this study, all catheters were calibrated using the retrodialysis 
method (18, 19). A more detailed description of MD can be found elsewhere (20).
In the present study, the MD system consisted of CMA 107 precision pumps (µ-Dialysis AB, 
Stockholm, Sweden) and CMA 63 catheters (membrane length 10 mm, molecular cut-off 20 kilo 
Daltons). When surgery was completed, the MD catheters were perfused with 0.9% NaCl containing 
cefuroxime at a concentration of 5 µg/mL (provided by the pharmacy at Aarhus University Hospital) 
at a perfusion rate of 2 μL/min. After a 30-min tissue equilibration period, all catheters were 
individually calibrated by collecting a sample over a 30-min interval. RR was calculated using the 
following equation: �� (%) = 100 × (1 ― ��������������������)
where Cdialysate is the cefuroxime concentration (µg/mL) in the dialysate and Cperfusate is the 
concentration (µg/mL) in the perfusate. Following calibration, the perfusate was changed to blank 
0.9% NaCl, and a 110-min washout period was allowed for. During the last 40 min of this period, two 
20-min dialysates were collected in order to evaluate and quantify the effectiveness of washout. 
Cefuroxime was then administered according to the randomization, which took place during the 
washout period. Regardless of group, dialysates were collected with 30-min intervals for 8 h starting 
at the initiation of cefuroxime infusion. Dialysate concentrations of cefuroxime were considered to 
represent the concentration at the midpoint of the sampling interval. For the subsequent data analysis, 
the absolute tissue concentrations (µg/mL), Ctissue, were calculated by correcting the dialysates for RR 
using the following equation:
    ������� =  ������������
In the middle of every dialysate sampling interval, a blood sample was drawn from a venous catheter 
in the cubital vein. Dialysates were immediately frozen and stored on dry ice for a maximum of 10 h, 
after which they were stored at -80°C until analysis. Venous blood samples were stored at 2-8C for a 
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maximum of 20 h before being centrifuged at 3,000 g for 10 min. Plasma aliquots were then frozen 
and stored at -80C until analysis.
Before removal of the catheters, a CT scan of the cortical drill hole in the anterior aspect of the tibia 
was conducted in order to verify that the drill hole had not penetrated to the bone marrow, and that the 
catheter had not been displaced.
Quantification of cefuroxime concentrations
Dialysate and plasma concentrations of cefuroxime were quantified using a validated ultra high 
performance liquid chromatography assay. Briefly, intra- and interrun imprecisions were below 6.8% 
and 6.5% for dialysate (assessed at concentrations of 0.2, 2.5 and 10 µg/mL), and free plasma 
concentrations (assessed at concentrations of 9.2 and 37.7 µg/mL), respectively. The lower limit of 
quantification was 0.06 µg/mL in dialysates. A detailed description of the assay can be found 
elsewhere (15, 19).
Population pharmacokinetic modelling
One- and two-compartment models with zero’th and first order kinetics were explored in order to 
obtain the best description of the drug concentration in each tissue. An ordinary two-compartment 
model with first order kinetics, elimination from the second compartment only, and measurement in 
the first compartment was found to provide the best description of the free plasma concentrations. For 
the solid tissues, a two-compartment model with zeroth order appearance, first order clearance, no 
flow back into the first compartment, elimination from the second compartment only, and 
measurement in the second compartment provided the best description. For CI, the drug concentration 
in the solid tissues is given by the following equation:
������� (�) = {
�1�3(1 ―  �― �3�)                                     ,  � ≤ �0�1 ― �
  
��3 +  (�1 ― ��3 ��3 �0�1 ― � ―  �1�3)�― �3�,  � > �0�1 ― �
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where k1 is the appearance rate, k3 is the clearance rate, t is the time, I is the continuous infusion rate, 
and x0 is the plasma concentration at time 0. The restriction k1>I was made in order to exclude the 
scenario of a steady drug concentration increase in the first compartment. For free plasma, the drug 
concentration is given by:
�������(�) =  (�1 +  �)(��0 + �)�(� ― �)  ��� ―  (�1 +  �)(��0 + �)�(� ― �)  ��� +  (�2 +  �3)��1�3
where 
 � = ― (�1 + �2 + �3) +  (�1 + �2 + �3)2 ― 4�1�32 ,                      � = ― (�1 + �2 + �3) ―  (�1 + �2 + �3)2 ― 4�1�32
and k2 is the rate constant associated with the flow from the second to the first compartment. In the 
case of STI, the drug concentration is obtained from the expressions above by putting I equal to zero. 
Based on these expressions, AUC0 - ∞ and target attainment for any given target could be determined. 
Statistical analysis
Using a non-linear mixed effects regression model with a random patient effect for each of the model 
parameters (x0, k1, k3  - k2 in case of plasma - and I in connection with continuous infusion) the two-
compartment models were fitted to the drug concentration data separately for the different tissues. 
The concentrations in the washout samples were low, and therefore neglected in the analysis. For a 
range of relevant MICs, Monte Carlo simulation was used to determine the probability of target 
attainment (PTA) for 65% (low target) and 90% fT > MIC (high target) for the observation period of 8 
h and 95% confidence intervals for AUC0 - ∞ and the ratio between AUCs0 - ∞ (21). More specifically, 
50000 curves were simulated from the asymptotic multivariate normal distribution of the parameter 
estimates, and the relevant quantities were calculated for each simulation. Tests for no difference 
between STI and CI with respect to AUC0 - ∞ and the ratio between AUCs0 - ∞ were based on the 
simulated 95%-confidence intervals and the normal distribution. The acceptable level of PTA is 
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debatable, but 90% is generally considered as adequate and thus applied in this study (22). The data 
were analyzed using R (R v 3.0.2, R core team, Vienna, Austria) with the package nlme.
Results
No MD or cefuroxime adverse related events were encountered. The flow of patients through the 
study is shown in figure 1. Reasons for exclusion from analysis of all dialysates from a microdialysis 
catheter were: blood in all dialysates, displacement of the catheter from the drill hole, bone marrow 
penetration of the cortical drill hole, and no flow through the catheter after connection to the pump. 
Patient characteristics can be found in table 1.
Mean (SD) in vivo RRs were 11 (5) %, 22 (10) % and 14 (6) %, for SCT, cancellous and cortical bone 
respectively. The mean (SD) concentrations in the first and second washout samples were 0.15 (0.28) 
µg/mL and 0.11 (0.16) µg/mL, 0.09 (0.19) µg/mL and 0.06 (0.12) µg/mL and 0.24 (0.26) µg/mL and 
0.17 (0.17) µg/mL for the corresponding anatomical sites, respectively. 
Observed concentrations and modelled concentration-time profiles are depicted in figure 2. Observed 
vs. fitted cefuroxime concentrations are shown in figure 3. These plots demonstrate that the model 
provides a satisfactory description of the cefuroxime concentration data.
Comparisons of AUCs0 - ∞ and tissue penetration ratios can be found in table 2. Tissue penetration was 
incomplete for SCT and cortical bone in the STI group. In the CI group, low SCT and cortical bone 
penetration were also found, but in this group, the findings were not statistically significant. No 
significant differences in AUCs and tissue penetration ratios were found between the two groups. 
The probability of attaining the selected targets in the different tissues is shown in figure 4 for a range 
of relevant MICs. Irrespective of MIC, tissue and target, CI leads to higher PTA compared to STI. 
Except for cancellous bone, the differences in PTA between the high and low target are negligeable 
for CI, whereas for STI, a substantial reduction is found.  For the European Committee on 
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Antimicrobial Susceptibility Testing (EUCAST) clinical  Staphylococcus aureus breakpoint MIC of 4 
μg/mL, STI leads to inadequate PTA in all tissues but cancellous bone (23).
Discussion
This is the first clinical study to assess concurrent cefuroxime pharmacokinetics in plasma, SCT and 
bone administered as STI and CI in male TKR patients. The study has a number of interesting 
findings. Using the clinical breakpoint MIC of 4 μg/mL for Staphylococcus aureus, traditional STI of 
1.5 g cefuroxime only leads to acceptable PTA in cancellous bone, but not in the remaining tissues. 
Even for the low target and a MIC of 2 μg/mL, STI does not lead to adequate PTA in plasma and 
SCT. When looking at figure 4, it appears that CI leads to improved PTA compared to STI 
irrespective of MIC and tissue. Also, except for cancellous bone, the difference in PTA is negliceable 
between the high and the low target for CI which is not the case for STI. Specifically, for the 
Staphylococcus aureus breakpoint, CI leads to adequate PTA for free plasma, SCT and cancellous 
bone even for the high target, while for cortical bone, a PTA of approximately 80% is achieved. 
Finally, it should be noted that both STI and CI leads to low PTAs for high organism MICs of  8 
μg/mL. From a pharmacokinetic point of view, this study therefore suggests that CI of a standard dose 
of 1.5 g of cefuroxime may provide superior antibiotic prophylaxis in male TKR patients compared to 
traditional STI infusion. 
 
While the time-dependency and plasma targets for treatment of infection are well-established for 
cefuroxime, specific tissue targets for prevention of postoperative orthopaedic infections remain 
somewhat unknown (1, 7). For time-dependent drugs, which are commonly used for antibiotic 
surgical prophylaxis, it is, however, recommended that not only plasma but also tissue concentrations 
exceed planktonic MIC values of relevant pathogens throughout the surgical procedure (1). In relation 
to total hip replacement, a practice of administering time-dependent antibiotics four times within the 
first 24 h of surgery has, retrospectively, been shown to lower postoperative infection rates compared 
to a single preoperative dose (24). The latter suggests that a single preoperative dose may be 
insufficient to eradicate the entire surgical site bacterial inoculum, and that the time with 
concentrations above MIC during the first 24 h may play a role in antibiotic prophylaxis in joint 
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replacement surgery. These speculations are somewhat supported by our findings of rather low PTA 
with STI for MICs ≤ 4 μg/mL. Furthermore, the severity of PJIs in itself calls for adoption of 
validated treatment targets instead of only sustaining antibiotic concentrations above the MIC during 
surgery. Finally, it could be speculated that antibiotics are ineffective against bacterial dormancy that 
may occur instantly following perioperative inoculation. In that case, prolonged time with 
concentrations above relevant MICs may have a positive effect in lowering postoperative infections 
rates. Based on these considerations, our application of a traditional 65% fT>MIC target and a more 
aggressive 90% fT>MIC target for evaluation of postoperative tissue pharmacokinetics in TKR patients 
and concurrent comparison of CI and STI therefore seems reasonable. Though a target of 100% 
fT>MIC appears fundamental for a CI approach, this would not be possible to obtain with the present 
setup due to time delays associated with the 5 min bolus infusion and the distribution from plasma to 
tissue.
Incomplete and uneven tissue distribution of antibiotics has been demonstrated for various 
combinations of drug and tissue and under different conditions, including infection (8, 16, 17, 25). In 
this study, low SCT and cortical bone penetration were found in both the STI and the CI group, but 
the findings were only significant in the STI group. Nonetheless, our findings support that a 
homogeneous tissue distribution of antibiotics cannot be taken for granted, particularly in special 
situations like surgery. This emphasize the importance of antibiotic pharmacokinetic studies 
evaluating specific drug and tissue concentrations under different conditions. 
Males undergoing TKR surgery is a rather selected group that does not reflect the average population. 
Consequently, the results can only safely be regarded as representative for this specific population and 
the actual situation of TKR surgery. The tissue pharmacokinetics may have been affected by the local 
injection of adrenaline and ropivacaine at the end of surgery as both drugs induces vasoconstriction. 
Also, MD sampling of antibiotics in bone has to await surgical creation of drill holes. Consequently, 
measurements could not be obtained during the TKR surgery. Nonetheless, the present data obtained 
in drill holes shortly following the end of surgery seems to be reflective of the true postoperative 
situation. 
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In pharmacokinetic MD studies, a correction for RR is required in order to obtain absolute 
concentrations. This leads to a magnification of the variations associated with the preanalytical 
sample handling and the chemical assay. We have previously found comparable variations between 
plasma and tissue pharmacokinetic parameters, but in this study, the variations in tissue 
pharmacokinetic parameters were higher than those found in plasma. This is in accordance with 
findings in other clinical studies (9, 26). Given the RR-related magnification of the variations, the 
surgical trauma, local injection of adrenalin and the well-known biological variation, the sizes of the 
tissue variations illustrated in figure 2 and by the 95%-CIs of the AUCs in table 2 are not surprising, 
and supposedly not an indication of inadequate precision of the methodological setup nor a poor 
model description of the data. 
In summary, this pharmacokinetic study shows that CI of 1.5 g of cefuroxime leads to improved 
probability of attaining relevant pharmacokinetic targets in male TKR  patients compared to 
traditional STI. In fact, standard STI results in considerably inadequate PTA when applying the 
clinical Staphylococcus aureus MIC breakpoint. These findings suggest that application of CI may 
improve antibiotic prophylaxis for TKR patients. 
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Figure 1.  Patient flow.
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Figure 2. Observed concentrations (dots) and modelled concentration-time profiles (solid lines).
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Figure 3.  Observed versus fitted individual- and population cefuroxime concentrations for free plasma, SCT, cortical and 
cancellous bone.
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Figure 4. Probability of target attainment in the different tissues. A horizontal line representing 90 % of patients with 
concentrations above MIC have been inserted. 
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Table 1
Patient characteristics. 
Variable Short-term infusion Continuous infusion
Number of patients 9 9
Age (years), mean (range) 68.7 (58 – 76) 70.0 (60 – 75)
Height (cm), mean (range) 180 (170 – 190) 176 (169 – 183)
Weight (kg), mean (range) 99 (73 – 110) 89 (73 – 107)
Body mass index (kg/m2), mean (range) 30.6 (21.8 – 36.0) 28.7 (23.9 – 35.8)
Plasma creatinine (μmol/l), mean (range) 76 (64 – 99) 87 (68 – 111)
Plasma albumin (g/l), mean (range) 42 (38 – 47) 42 (40 – 46)
Table 2
Comparison of AUC and tissue penetration
Parameter STI CI P-value
Free plasma AUC0 - ∞ (min µg/mL) 5801 (4902-7277) 5415 (4625-6670) p = 0.63
SCT AUC0 - ∞ (min µg/mL) 3016 (1929-4675) 3764 (2164-6426) p = 0.56
Cancellous bone AUC0 - ∞ (min µg/mL) 6035 (3718-9831) 6256 (4276-8954) p = 0.91
Cortical bone AUC0 - ∞ (min µg/mL) 2630 (1746-3945) 3557 (1375-7262) p = 0.56
SCT fAUCtissue/fAUCplasma 0.52 (0.32-0.83) 0.69 (0.38-1.21) p = 0.48
Cancellous bone fAUCtissue/fAUCplasma 1.03 (0.61-1.74) 1.15 (0.74-1.71) p = 0.76
Cortical bone fAUCtissue/fAUCplasma 0.35 (0.28-0.70) 0.65 (0.25-1.36) p = 0.50
AUC0 – ∞, area under the concentration–time curve from 0 to infinity; fAUCtissue/fAUCplasma, tissue penetration expressed as 
the ratio of free AUC0 - ∞ tissue to free AUC0 - ∞ plasma. Values are given as mean (95% confidence intervals). 
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